

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

B&K CORPORATION LIMITED
青城新藥生物科技（青島）股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 2396)

APPOINTMENT OF CHIEF EXECUTIVE OFFICER
AND
CLOSURE OF REGISTER OF MEMBERS

The board (the “**Board**”) of directors (the “**Director(s)**”) of B&K Corporation Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that Ms. Jia Lijia (“**Ms. Jia**”), being the chairperson of the Board and an executive Director, has been appointed as the chief executive officer (“**CEO**”) of the Company with effect from 20 October 2026. Her term of office as the CEO will end on the date when the term of office of the first session of the Board expires.

The biographical details of Ms. Jia are as follows:

Ms. Jia, aged 58, is the founder of the Group and has served as the Director and the chairperson of the Board since the establishment of the Company in April 2012. She was re-designated as an executive Director in April 2024. She is primarily responsible for providing leadership and governance of the Board, and responsible for the overall business strategies and management of the Group. Ms. Jia is the chairperson of the internal control committee of the Board and a member of each of the remuneration committee and the nomination committee of the Board. She currently also serves as director of Huaren Yihai Biotechnology (Beijing) Co., Ltd. (華仁益海生物科技(北京)有限公司), BNK Corporation Limited (香港華人新藥生物技術有限公司) and Hainan Huaren Biotechnology Co., Ltd. (海南華人生物技術有限公司), each being a wholly-owned subsidiary of the Company.

Ms. Jia has over 27 years of experience in the pharmaceutical industry. Prior to the establishment of the Group, Ms. Jia served as a sales manager at Mudanjiang Lingtai Medicdment Co., Ltd. (Beijing Branch) (牡丹江靈泰藥業股份有限公司(北京辦事處)) from January 1997 to September 2004. Ms. Jia then served as a deputy general manager at Beijing Sheng Hongye Pharmaceutical Technology Development Co., Ltd. (北京盛宏業醫藥科技發展有限公司), a company primarily engaged in pharmaceutical technology development, from October 2004 to December 2010, where she was primarily responsible for sales and operation management.

Ms. Jia obtained a degree of Master of Business Administration from Macau University of Science and Technology (澳門科技大學) in Macau, the People's Republic of China in June 2007.

Ms. Jia is the mother of Mr. Wang Kelong (“**Mr. Wang**”), who is an executive Director.

As at the date of this announcement, Ms. Jia will not receive additional remuneration in her capacity as the CEO. Ms. Jia's remuneration will be subject to review on a periodical basis by the Board and the remuneration committee of the Board with reference to, among others, the prevailing market condition, competence, the time commitment and responsibilities involved, remuneration paid by comparable companies and the employment conditions within the Group for other positions.

As at the date of this announcement, Ms. Jia is interested in 66,995,937 shares (the “**Share(s)**”) of the Company, of which (a) 19,540,937 Shares were held by Ms. Jia; (b) 17,980,000 Shares were held by Mr. Wang; (c) 17,475,000 Shares were held by Ms. Zhang Hongbo (“**Ms. Zhang**”); and (d) 12,000,000 Shares were held by Mr. Li Gewei (“**Mr. Li**”). On 16 April 2024, Ms. Jia, Mr. Wang, Ms. Zhang and Mr. Li entered into the concert party agreement to acknowledge and confirm, among other things, that they will continue to communicate thoroughly and act in concert by aligning their votes at the Board meetings and shareholders' meetings of the Company. As such, each of Ms. Jia, Mr. Wang, Ms. Zhang and Mr. Li is deemed to be interested in such Shares held by each other as they are parties acting in concert.

As at the date of this announcement, save as disclosed above, Ms. Jia (i) has not held any other position with the Company or other members of the Group; (ii) has not held any directorships in other public companies, the securities of which are listed on any securities market in Hong Kong or overseas, in the last three years; (iii) has no other major appointments or professional qualifications; (iv) does not have any relationships with any Director, member of senior management, substantial shareholder or controlling shareholder (having the meaning ascribed to it under the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”)) of the Company; and (v) does not have any interest in shares, underlying shares or debentures of the Company or any of its associated corporations within the meaning of Part XV of the Securities Futures Ordinance (Chapter 571 of the laws of Hong Kong).

Save as disclosed above, Ms. Jia has confirmed that there are no matters that need to be brought to the attention of the shareholders of the Company, and there is no other information in relation to aforesaid appointment as the CEO that is required to be disclosed pursuant to Rule 13.51(2)(h) to (v) of the Listing Rules.

The Company would like to welcome Ms. Jia on her appointment as the CEO.

CLOSURE OF REGISTER OF MEMBERS

The Board hereby announces that the Company proposes to convene the third extraordinary general meeting (the “EGM”) for the year 2026 on Friday, 6 November 2026.

In order to determine the entitlement to attend and vote at the EGM, the register of members of the Company will be closed from Tuesday, 3 November 2026 to Friday, 6 November 2026, both days inclusive, during which period no transfer of shares of the Company will be effected. The record date for determining the eligibility to attend and vote at the EGM will be 6 November 2026. For holders of H Shares who wish to attend and vote at the EGM, the relevant share certificates accompanied by all transfer documents must be lodged with the Company’s H Share registrar, Tricor Investor Services Limited, at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong no later than 4:30 p.m. on Monday, 2 November 2026.

A circular containing details of the resolution to be proposed at the EGM, together with the notice of the EGM, will be published in due course, and despatched to the holders of H shares in the manner in which the holders of H Shares have elected to receive corporate communications.

By order of the Board
B&K Corporation Limited
Ms. JIA Lijia
*Chairperson, Executive Director and
Chief Executive Director*

Qingdao, the PRC
20 October 2026

As at the date of this announcement, the Board comprises (i) Ms. JIA Lijia, Mr. WANG Kelong, Dr. ZHAI Junhui and Mr. MIAO Tianxiang as executive Directors; (ii) Ms. LIN Ying and Mr. YUAN Fei as non-executive Directors; and (iii) Mr. FOK Chi Tat Michael, Mr. LI Jiayan and Mr. YUE Yichun as independent non-executive Directors.